Table 2: Adjusted odds ratios with 95% confidence intervals (CI) and associated P values from the logistic regression predicting pathologic category T2b in the 203 study cohort patients.

Clinical characteristicsNo. of patientsNo. of events( of patients)Univariable analysisMultivariable analysis
UOR (95 CI)P AOR (95 CI)p

Age(y)20347(23.2)1.05(1.02-1.09)0.0011.05(1.01-1.09)0.009

Parity20347(23.2)0.99(0.76-1.31)0.992

BMI20347(23.2)1.04(0.95-1.13)0.424

Cesarean section

 No17542(24)10.476

 Yes285(17.9)0.69(0.25-1.92)

History of at least one normal delivery2030.401

 No319(29)1

 Yes17238(22.1)0.69(0.29-1.63)

Menopause2030.007

 No10516(15.2)1

 Yes9831(31.6)2.57(1.30-5.09)

Histology0.374

 Squamous14331(21.7)1

 Adenocarcinoma5115(29.4)1.51(0.73-3.09)

 Adenosquamous91(11.1)0.45(0.05-3.75)

Grade0.45

 1287(25)1

 211124(21.6)0.83(0.32-2.18)

 34910(20.4)0.77(0.26-2.31)

 Unknown156(40)2.00(0.52-7.65)

SCC ag(ng/mL)20347(23.2)1.04(1.01-1.06)0.012

MRI T stage<0.0001

 T1b10316(11.5)1

 T2a102(20)1.92(0.38-9.86)

 T2b5429(53.7)8.92(4.23-18.82)

Clinical FIGO stage<0.0001

 IB112620(15.8)1

 IB25219(36.5)7.41(3.04-16.12)

 IIA1123(25)2.67(0.65-11.03)

 IIA2135(38.5)5.00(1.44-17.41)

MRI tumor size 20347(23.2)1.84(1.46-2.32)<0.0001

MRI pelvic LN involvement0.013

 Negative17134(19.9)1

 Positive3213(40.6)2.76(1.24-6.13)

MRI parametrial invasion<0.00010.002

 No14618(12.3)11

 Yes5729(50.9)7.37(3.59-15.08)3.77(1.62-8.79)

MRI parametrial invasion<0.0001

 Negative14617(11.6)1

 Unilateral4621(45.7)6.37(2.95-13.76)

 Bilateral119(81.8)34.15(6.80-171.43)

MRI vaginal involvement0.60

 No19344(22.8)1

 Yes103(30)1.45(0.36-5.85)

MRI uterine corpus invasion<0.0001<0.0001

 No16219(11.7)11

 Yes4128(68.3)16.21(7.19-36.57)9.99(4.11-24.32)